BRAF and cancer: The disappointing results achieved using the BRAF(V600E)-specific inhibitor Vemurafenib in CRC patients not only showed the importance of these feedbacks in vivo, but also demonstrated the different wiring of oncogenic networks in cancers of either neuroectodermal or epithelial origin such as melanoma and CRC, respectively.